Mircette 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Mircette 28 Day are increasingly presenting to offices, telehealth portals, and pharmacy pick-up lines frustrated and empty-handed. While the drug is not on the FDA's official shortage list, the combination of brand discontinuation, niche generic manufacturing, and inconsistent pharmacy stocking has created a practical access problem that prescribers need to be aware of — and have a plan to address.

Current Status: Brand Discontinued, Generics Technically Available

The brand-name Mircette (desogestrel 0.15mg/ethinyl estradiol 0.02mg with a 5-day low-dose EE tail; 21/2/5 pack) was voluntarily discontinued by the manufacturer. The FDA has approved multiple generic equivalents currently on the market: Kariva, Azurette, Viorele, Volnea, Pimtrea, Kimidess, Bekyree, and Simliya. These products are bioequivalent to the original Mircette.

Despite this, patients frequently report being unable to fill prescriptions at their local pharmacies. This occurs because: (1) only a small number of manufacturers produce this biphasic formulation; (2) retail chains often stock only one or two preferred generics in any drug class; and (3) the multiple trade names cause name-matching failures at the pharmacy counter when prescriptions are written for "Mircette."

Prescribing Strategies to Improve Patient Access

Several prescribing modifications can significantly improve the likelihood that patients successfully fill their prescriptions:

Prescribe by generic name with substitution permitted: Write for "desogestrel 0.15mg/ethinyl estradiol 0.02mg (biphasic 21/2/5 pack)" with a note that substitution with any bioequivalent generic (Kariva, Azurette, Viorele, Volnea, Pimtrea) is permitted. This gives pharmacists maximum flexibility.

List multiple acceptable generic names: On e-prescriptions, include a note field listing equivalent generics. This ensures the pharmacist doesn't decline the prescription because "Mircette" specifically isn't in their system.

Avoid writing brand-only prescriptions: Since the Mircette brand is discontinued, a prescription written as "Mircette — brand necessary" cannot be filled. Ensure "dispense as written" is not checked for this medication unless you specifically want a particular generic.

Consider directing patients to mail-order: Mail-order pharmacy programs affiliated with insurance plans typically maintain broader generic inventories than retail locations and can supply 90-day fills.

Therapeutic Substitution: When Direct Equivalents Aren't Available

If all direct generic equivalents are unavailable in a patient's area, the following therapeutic alternatives merit consideration:

Apri / Desogen / Reclipsen (desogestrel 0.15mg/EE 0.03mg, monophasic): Same progestin, slightly higher EE dose. Widely available. Appropriate for most patients who were tolerating Mircette well.

Yaz / Beyaz / Loryna (drospirenone 3mg/EE 0.02mg): Different progestin class with anti-androgenic properties. May be preferred in patients with PMDD or acne concerns. Monitor for potassium in patients on ACE inhibitors or ARBs.

Lo Loestrin Fe (norethindrone acetate 1mg/EE 0.01mg): Ultra-low EE option; consider for patients with estrogen-sensitive conditions or side effect history.

NuvaRing / EluRyng (etonogestrel 0.12mg/EE 0.015mg/day, vaginal ring): Monthly ring. Same hormone classes via different route; etonogestrel is the active metabolite of desogestrel. Useful if adherence to daily dosing is a concern.

Counseling Patients on Transition

When switching a patient from Mircette to a generic equivalent or therapeutic alternative, key counseling points include:

Start the new pack on the same day they would have started their next Mircette pack

Use backup contraception for 7 days when switching to a different formulation class

Expect possible adjustment symptoms (irregular spotting, nausea changes) for the first 1–2 cycles with any new formulation

For patients on direct generic equivalents (same formulation), no backup is needed and the switch is seamless

Insurance and Prior Authorization Considerations

Under the ACA, most non-grandfathered health plans must cover FDA-approved contraceptives without cost-sharing. If a patient's plan only covers specific generics on its formulary, providers can submit a formulary exception request if the preferred generic is unavailable. Document the availability issue in the patient's chart to support the exception request.

How medfinder Supports Providers and Patients

medfinder helps providers direct patients to pharmacies that actually have their medication in stock. Rather than sending a patient to a pharmacy that can't fill the prescription, providers can recommend medfinder.com/providers as a resource. For more guidance on supporting patients through the process, see our article on how to help your patients find Mircette 28 Day in stock.